Company: INKT
Filing Date: 2025-07-15
Form Type: 424B5
Source: 0001193125-25-159014
Chunk: 23

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-07-15
Form: 424B5
Chunk 23
---
 circumstances may be materially different from what we expect.

6

USE OF PROCEEDS

Except as otherwise provided in the applicable prospectus supplement relating to a specific offering, we intend to use the net proceeds from the sale of
securities by us under this prospectus for working capital and other general corporate purposes. General corporate purposes may include, without limitation, research and development expenditures, preclinical and clinical development and
commercialization of our product candidates, the acquisition or in-licensing of products or product candidates, business or technologies, collaborations, working capital and capital expenditures. We
may temporarily invest the net proceeds we receive in short-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government and its agencies.

We have not determined the amount of net proceeds to be used specifically for such purposes. As a result, management will have broad discretion in the
application of the net proceeds we may receive, and investors will be relying on the judgment of our management regarding the application of our net proceeds. Additional information on the use of net proceeds from the sale of securities by us under
this prospectus may be set forth in the prospectus supplement relating to the specific offering.

7

PLAN OF DISTRIBUTION Our Plan of Distribution We may sell the securities, from time to time, to or through underwriters or dealers, through agents or remarketing firms, or directly to one or more purchasers pursuant to:

| • |     | underwritten public offerings; |

| • |     | negotiated transactions; |

| • |     | block trades; |

| • |     | “at the market offerings,” within the meaning of Rule 415(a)(4) of the Securities Act of 1933, as 
 amended, or the Securities Act, into an existing trading market, at prevailing market prices; or  |

| • |     | through a combination of these methods. |

We may sell the securities to or through one or more underwriters or dealers (acting as principal or agent), through agents, or directly to one or more purchasers. We may distribute securities from time to time in one or more transactions:

| • |     | at a fixed price or prices, which may be changed; |

| • |     | at market prices prevailing at the time of sale; |

| • |     | at prices related to such prevailing market prices; or |

| • |     | at negotiated prices. |

A prospectus supplement or supplements (and any related free writing prospectus that